Literature DB >> 31091442

Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation.

Christina A Ortmann1, Lena Dorsheimer1, Khalil Abou-El-Ardat2, Jennifer Hoffrichter1, Birgit Assmus3, Halvard Bonig4, Anica Scholz5, Heike Pfeifer1, Hans Martin1, Tobias Schmid5, Bernhard Brüne5, Sebastian Scheich1, Björn Steffen1, Julia Riemann1, Stella Hermann6, Alexandra Dukat7, Gesine Bug1, Christian H Brandts8, Sebastian Wagner2, Hubert Serve2, Michael A Rieger9.   

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is caused by recurrent somatic mutations leading to clonal blood cell expansion. However, direct evidence of the fitness of CHIP-mutated human hematopoietic stem cells (HSCs) in blood reconstitution is lacking. Because myeloablative treatment and transplantation enforce stress on HSCs, we followed 81 patients with solid tumors or lymphoid diseases undergoing autologous stem cell transplantation (ASCT) for the development of CHIP. We found a high incidence of CHIP (22%) after ASCT with a high mean variant allele frequency (VAF) of 10.7%. Most mutations were already present in the graft, albeit at lower VAFs, demonstrating a selective reconstitution advantage of mutated HSCs after ASCT. However, patients with CHIP mutations in DNA-damage response genes showed delayed neutrophil reconstitution. Thus, CHIP-mutated stem and progenitor cells largely gain on clone size upon ASCT-related blood reconstitution, leading to an increased future risk of CHIP-associated complications.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASCT; CHIP; autologous stem cell transplantation; chemotherapy; clonal dominance; clonal hematopoiesis; hematopoietic stem cells; hematopoietic stress; leukemia; somatic mutations

Mesh:

Year:  2019        PMID: 31091442     DOI: 10.1016/j.celrep.2019.04.064

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  14 in total

1.  The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.

Authors:  Doriana Gramegna; Diego Bertoli; Chiara Cattaneo; Camillo Almici; Alessandro Re; Angelo Belotti; Erika Borlenghi; Gaetana Lanzi; Silvana Archetti; Rosanna Verardi; Duilio Brugnoni; Margherita Sciumè; Rosa Daffini; Aldo M Roccaro; Alessandra Tucci; Giuseppe Rossi
Journal:  Ann Hematol       Date:  2022-04-05       Impact factor: 3.673

2.  [Clonal hematopoiesis: causes and clinical implications].

Authors:  Andreas Burchert
Journal:  Inn Med (Heidelb)       Date:  2022-08-15

Review 3.  Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-09-01       Impact factor: 3.122

Review 4.  [Relevance of clonal hematopoiesis for cellular therapies].

Authors:  Raphael Teipel; Malte von Bonin; Friedrich Stölzel; Johannes Schetelig; Christian Thiede; Martin Bornhäuser
Journal:  Inn Med (Heidelb)       Date:  2022-09-23

Review 5.  Clonal hematopoiesis: Mutation-specific adaptation to environmental change.

Authors:  Marcus A Florez; Brandon T Tran; Trisha K Wathan; James DeGregori; Eric M Pietras; Katherine Y King
Journal:  Cell Stem Cell       Date:  2022-06-02       Impact factor: 25.269

6.  Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD.

Authors:  Stefan Kuhnert; Siavash Mansouri; Michael A Rieger; Rajkumar Savai; Edibe Avci; Gabriela Díaz-Piña; Manju Padmasekar; Mario Looso; Stefan Hadzic; Till Acker; Stephan Klatt; Jochen Wilhelm; Ingrid Fleming; Natascha Sommer; Norbert Weissmann; Claus Vogelmeier; Robert Bals; Andreas Zeiher; Stefanie Dimmeler; Werner Seeger; Soni S Pullamsetti
Journal:  Cells       Date:  2022-07-05       Impact factor: 7.666

7.  Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation.

Authors:  Johannes Frasez Soerensen; Anni Aggerholm; Gitte Birk Kerndrup; Marcus Celik Hansen; Ina Kathrine Lykke Ewald; Marie Bill; Lene Hyldahl Ebbesen; Carina Agerbo Rosenberg; Peter Hokland; Maja Ludvigsen; Anne Stidsholt Roug
Journal:  Blood Adv       Date:  2020-03-10

Review 8.  The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.

Authors:  Mariam T Nawas; Johannes Schetelig; Frederik Damm; Ross L Levine; Miguel-Angel Perales; Sergio A Giralt; Marcel R VanDenBrink; Maria E Arcila; Ahmet Zehir; Elli Papaemmanuil; Anja Klussmeier; Alexander H Schmidt; Stephanie Maiwald; Kelly L Bolton; Roni Tamari
Journal:  Blood Rev       Date:  2020-08-24       Impact factor: 8.250

9.  Clonal hematopoiesis in sickle cell disease.

Authors:  Thomas Pincez; Simon S K Lee; Yann Ilboudo; Michael Preuss; Anne-Laure Pham Hung d'Alexandry d'Orengiani; Pablo Bartolucci; Frédéric Galactéros; Philippe Joly; Daniel E Bauer; Ruth J F Loos; R Coleman Lindsley; Guillaume Lettre
Journal:  Blood       Date:  2021-11-25       Impact factor: 25.476

Review 10.  Clonal hematopoiesis and its emerging effects on cellular therapies.

Authors:  Malte von Bonin; Helena Klara Jambor; Raphael Teipel; Friedrich Stölzel; Christian Thiede; Frederik Damm; Frank Kroschinsky; Johannes Schetelig; Triantafyllos Chavakis; Martin Bornhäuser
Journal:  Leukemia       Date:  2021-07-02       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.